Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 3/20 | 0.57 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.57 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.54 |
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.51 |
| ▸ | P2RY10 | O00398 | 2/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.44 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4853808 | 0.93 | NOS1 (0.56) | GRIK1GRIK2SLC1A2SLC1A1NOS3 | |
| SCHEMBL4853803 | 0.93 | NOS1 (0.56) | GRIK1GRIK2SLC1A2SLC1A1NOS3 | |
| SCHEMBL8063263 | 0.87 | GSR (0.52) | GRIK1GRIK2SLC1A2SLC1A1NOS3 | |
| SCHEMBL10136300 | 0.86 | CES2 (0.52) | GRIK1GRIK2SLC1A2SLC1A1NOS3 | |
| SCHEMBL20751441 | 0.85 | NOS1 (0.59) | GRIK1GRIK2SLC1A2SLC1A1NOS3 | |
| SCHEMBL21952409 | 0.85 | NOS1 (0.59) | GRIK1GRIK2SLC1A2SLC1A1NOS3 | |
| Aspartic Acid SCHEMBL27938168 | 0.84 | GRIK1 (0.51) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL19951694 | 0.84 | P2RY10 (0.56) | GRIK1GRIK2SLC1A2SLC1A1NOS3 | |
| SCHEMBL10073281 | 0.84 | P2RY10 (0.56) | GRIK1GRIK2SLC1A2SLC1A1NOS3 | |
| SCHEMBL12203832 | 0.84 | P2RY10 (0.56) | GRIK1GRIK2SLC1A2SLC1A1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566494-B1 | CXCR4 RECEPTOR COMPOUNDS | ACER THERAPEUTICS INC (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-2566494-B1 | CXCR4 RECEPTOR COMPOUNDS | ACER THERAPEUTICS INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20160159861-A1 | APJ Receptor Compounds | ANCHOR THERAPEUTICS, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159861-A1 | APJ Receptor Compounds | ANCHOR THERAPEUTICS, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| EP-3021861-A1 | APJ RECEPTOR COMPOUNDS | Anchor Therapeutics, Inc. (US) | 2016-05-25 | — | — | EP | disclosed |
| US-9155795-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9155795-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9096646-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096646-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| WO-2015010045-A1 | APJ RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2011106703-A2 | CXCR4 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| WO-2010053547-A2 | CXCR5 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010053547-A2 | CXCR5 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010053550-A2 | CXCR4 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010053548-A2 | PTHR1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010053548-A2 | PTHR1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010053546-A2 | CRF1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010053546-A2 | CRF1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010053545-A2 | APJ RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010053545-A2 | APJ RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159861-A1 | APJ Receptor Compounds | APLNR, AP1G1, AP2B1 | GRIK1 1073/4885GRIK2 1148/4885SLC1A2 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.